RT Journal Article
T1 Hereditary Optic Neuropathies: A Systematic Review on the Interplay between Biomaterials and Induced Pluripotent Stem Cells
A1 Ladero Galán, Miguel
A1 Reche Sainz, José Alberto
A1 Galardo Pérez, María Esther
AB Hereditary optic neuropathies (HONs) such as dominant optic atrophy (DOA) and Leber Hereditary Optic Neuropathy (LHON) are mitochondrial diseases characterized by a degenerative loss of retinal ganglion cells (RGCs) and are a cause of blindness worldwide. To date, there are only limited disease-modifying treatments for these disorders. The discovery of induced pluripotent stem cell (iPSC) technology has opened several promising opportunities in the field of HON research and the search for therapeutic approaches. This systematic review is focused on the two most frequent HONs (LHON and DOA) and on the recent studies related to the application of human iPSC technology in combination with biomaterials technology for their potential use in the development of RGC replacement therapies with the final aim of the improvement or even the restoration of the vision of HON patients. To this purpose, the combination of natural and synthetic biomaterials modified with peptides, neurotrophic factors, and other low- to medium-molecular weight compounds, mimicking the ocular extracellular matrices, with human iPSC or iPSC-derived cell retinal progenitors holds enormous potential to be exploited in the near future for the generation of transplantable RGC populations.
PB MDPI
YR 2024
FD 2024-01-03
LK https://hdl.handle.net/20.500.14352/104967
UL https://hdl.handle.net/20.500.14352/104967
LA eng
NO Ladero, Miguel, Jose Alberto Reche-Sainz, y M. Esther Gallardo. «Hereditary Optic Neuropathies: A Systematic Review on the Interplay between Biomaterials and Induced Pluripotent Stem Cells». Bioengineering 11, n.o 1 (3 de enero de 2024): 52. https://doi.org/10.3390/bioengineering11010052.
NO 2023 Descuento MDPI
NO Horizon 2020
NO Agencia Estatal de Investigación
NO Ministerio de Ciencia, Innovación y Universidades(España)
NO Fondo de Investigación Sanitaria
NO Instituto de Salud Carlos III
NO European Comission
DS Docta Complutense
RD 9 abr 2025